Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection | ||
| dc.conicet.organizacion | University of Texas at San Antonio | |
| dc.conicet.organizacion | University of Texas at San Antonio | |
| dc.conicet.organizacion | Comenius University | |
| dc.conicet.organizacion | Hospital Universitario de Canarias | |
| dc.conicet.organizacion | Margen Clinic | |
| dc.conicet.organizacion | Alcasian Care Enterprises | |
| dc.conicet.organizacion | University Of Alabama At Birmingahm. School Of Medicine | |
| dc.conicet.organizacion | University Of Münster | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Juan | |
| dc.conicet.organizacion | Universidad Catolica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo | |
| dc.conicet.organizacion | Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Farmacología | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires" | |
| dc.contributor.author | Reiter, Russel | |
| dc.contributor.author | Sharma, Ramaswamy | |
| dc.contributor.author | Simko, Fedor | |
| dc.contributor.author | Dominguez Rodriguez, Alberto | |
| dc.contributor.author | Tesarik, Jan | |
| dc.contributor.author | Neel, Richard L. | |
| dc.contributor.author | Slominski, Andrzej T. | |
| dc.contributor.author | Kleszczynski, Konrad | |
| dc.contributor.author | Martín Giménez, Virna Margarita | |
| dc.contributor.author | Manucha, Walter Ariel Fernando | |
| dc.contributor.author | Cardinali, Daniel Pedro | |
| dc.date.issued | 2022-03 | |
| dc.description.abstract | Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efficacy in preventing or treating this serious condition and all have side effects to differing degrees. We encourage the continued consideration of the use of the antioxidant and anti-inflammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientific publications have identified melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral effects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous different viruses, including three different coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most effective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profile over a wide range of doses and lacks significant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially beneficial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2. | es |
| dc.description.fil | Fil: Reiter, Russel. University of Texas at San Antonio; Estados Unidos | |
| dc.description.fil | Fil: Sharma, Ramaswamy. University of Texas at San Antonio; Estados Unidos | |
| dc.description.fil | Fil: Simko, Fedor. Comenius University; Eslovaquia | |
| dc.description.fil | Fil: Dominguez Rodriguez, Alberto. Hospital Universitario de Canarias; España | |
| dc.description.fil | Fil: Tesarik, Jan. Margen Clinic; España | |
| dc.description.fil | Fil: Neel, Richard L.. Alcasian Care Enterprises; Estados Unidos | |
| dc.description.fil | Fil: Slominski, Andrzej T.. University Of Alabama At Birmingahm. School Of Medicine; Estados Unidos | |
| dc.description.fil | Fil: Kleszczynski, Konrad. University Of Münster; Alemania | |
| dc.description.fil | Fil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Juan; Argentina. Universidad Catolica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; Argentina | |
| dc.description.fil | Fil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Cátedra de Farmacología; Argentina | |
| dc.description.fil | Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Reiter, Russel; Sharma, Ramaswamy; Simko, Fedor; Dominguez Rodriguez, Alberto; Tesarik, Jan; et al.; Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection; Birkhauser Verlag Ag; Cellular and Molecular Life Sciences; 79; 143; 3-2022; 1-12 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1420-682X | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/203352 | |
| dc.journal.ciudad | Basilea | es |
| dc.journal.number | 143 | es |
| dc.journal.pagination | 1-12 | es |
| dc.journal.pais | Suiza | es |
| dc.journal.title | Cellular and Molecular Life Sciences | es |
| dc.journal.volume | 79 | es |
| dc.language.iso | eng | es |
| dc.publisher | Birkhauser Verlag Ag | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/10.1007/s00018-021-04102-3 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s00018-021-04102-3 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/2.5/ar/ | * |
| dc.subject | CORONAVIRUS | es |
| dc.subject | COVID-19 | es |
| dc.subject | CYTOKINE STORM | es |
| dc.subject | HYPOXIA-INDUCIBLE FACTOR 1-Α | es |
| dc.subject | PHOSPHOLIPASE A2 | es |
| dc.subject | SEPSIS | es |
| dc.subject | VIRAL INFECTION | es |
| dc.subject.classification | Otras Ciencias de la Salud | es |
| dc.subject.classification | Ciencias de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.c5ff1bfc-c79a-449b-a14a-8a48c63c7aa2_B.pdf
- Tamaño:
- 1.2 MB
- Formato:
- Adobe Portable Document Format